Table 1.

Studies that have investigated the effect of PRRT on meningiomas.

Reference	Type of Study	Cohort	Response	PFS (Months)	OS (Months)	Adverse Events/Toxicity
Bartolomei et al. [6]	prospective	n = 29	stabilization n = 19 progression n = 10	6 (from end of PRRT)	40	white blood cells n = 18 renal n = 1
Hartrampf et al. [46]	prospective	n = 10	stabilization n = 7 progression n = 3	91.1	105	none
Kreissl et al. [47]	prospective	n = 10	stabilization n = 8 Partial remission n = 1 complete remission n = 1	-	-	none
Kertels et al. [48]	retrospective	n = 11	stabilization n = 6 no response n = 5	12	37	temporary leukopenia n = 53 thrombozytopenia n = 15 renal n = 3 liver n = 1
Seystahl et al. [50]	retrospective	n = 20	stabilization n = 10 progression n = 10	5.4	not reached	lymphocytopenia 70%

PFS: progression-free survival. OS: overall survival. PFS and OS are given as mean values.